ライフサイエンスコーパス: low-molecular-weight heparin

1 ers), and anticoagulants (unfractionated and low-molecular-weight heparins).

2 ncluding low-dose unfractionated heparin and low molecular weight heparin.

3 not altered by saturating concentrations of low molecular weight heparin.

4 unfractionated heparin or, less commonly, to low-molecular weight heparin.

5 ls that compared unfractionated heparin with low-molecular-weight heparin.

6 th direct oral anticoagulants, warfarin, and low-molecular-weight heparin.

7 ation until, in the 1990s, widespread use of low-molecular-weight heparin.

8 ral anticoagulants compared with warfarin or low-molecular-weight heparin.

9 ral anticoagulants compared with warfarin or low-molecular-weight heparin.

10 ypercoagulable state, which was treated with low-molecular-weight heparin.

11 analyses examined outpatient treatment with low-molecular-weight heparin.

12 ng complications compared with bridging with low-molecular-weight heparin.

13 7.3wt% of heparin and from 6.2 to 8.3wt% of low-molecular-weight heparin.

14 with venous thromboembolism are treated with low-molecular-weight heparins.

15 anticoagulant, is being rapidly displaced by low-molecular-weight heparins.

16 anism of action of the important therapeutic low-molecular-weight heparins.

17 Treatment options include warfarin and low-molecular-weight heparins.

18 use of glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins.

19 eeding complications, the odds ratio favored low-molecular-weight heparins (0.57 [CI, 0.33 to 0.99];

20 vs dabigatran 0.88 [0.59-1.36]; factor Xa vs low-molecular-weight heparin 1.02 [0.42-2.70]; and low-m

21 eceive bridging anticoagulation therapy with low-molecular-weight heparin (100 IU of dalteparin per k

22 ptor, by microinjection of single cells with low molecular weight heparin (5-50 mg/ml), blocked only

23 is on day 1 or 2 in hospital, typically with low-molecular weight heparin (56% of patients receiving

24 ants were used in 24% (n=665), predominantly low-molecular-weight heparin (73%, n=487) and unfraction

25 fXa to bind direct fXa inhibitors as well as low molecular weight heparin-activated antithrombin III

26 Low-molecular-weight heparins administered subcutaneousl

27 There are developments in the role of low-molecular-weight heparin agents in management of acu

28 ural bridging with unfractionated heparin or low-molecular-weight heparin aims to reduce the risk of

29 ion [PCI], glycoprotein IIb/IIIa inhibitors, low-molecular-weight heparin; all P<.001).

30 he thermodynamics of SLPI interaction with a low molecular weight heparin, an undersulfated decasacch

31 ective depolymerization to prepare new ultra low molecular weight heparin and coupling it with the or

32 iscusses controversies regarding the role of low molecular weight heparin and intensive statin regime

33 Low molecular weight heparin and the synthetic pentasacc

34 commonly used anti-coagulant drugs, such as low molecular weight heparin and warfarin, are effective

35 oagulant activity of both unfractionated and low molecular weight heparins and inhibited enzymatic su

36 sts for inpatient treatment were $26,516 for low-molecular-weight heparin and $26,361 for unfractiona

37 ding compared with sequential treatment with low-molecular-weight heparin and a vitamin K antagonist

38 Low-molecular-weight heparin and nonsteroidal anti-infla

39 Low-molecular-weight heparins and heparinoids are superi

40 ommended medications increased, particularly low-molecular-weight heparins and statins.

41 nt anticoagulants such as unfractionated and low-molecular-weight heparins and the vitamin K antagoni

42 Postdischarge use of low-molecular-weight-heparin and other anticoagulants wa

43 glycoprotein IIb/IIIa receptor antagonists, low molecular weight heparins, and coronary stents will

44 Parenteral unfractionated heparin, low-molecular-weight heparin, and fondaparinux are avail

45 ding aspirin, clopidogrel, unfractionated or low-molecular-weight heparin, and glycoprotein IIb/IIIa

46 ed inefficiently when PF4 was incubated with low-molecular-weight heparin, and none formed with the p

47 Low-molecular-weight heparins appear to be beneficial in

48 Low molecular weight heparins are a new class of anticoa

49 Heparin and the low molecular weight heparins are extensively used as me

50 All of the panels agree that low molecular weight heparins are preferred for the long

51 ombin (AT) binding properties of heparin and low molecular weight heparins are strongly associated to

52 ycoprotein IIb/IIIa inhibitors now exist and low molecular weight heparins are used more frequently w

53 Low molecular weight heparins are widely used to try to

54 Low-molecular-weight heparins are attractive alternative

55 Low-molecular-weight heparins are effective for treating

56 Low-molecular-weight heparins are highly cost-effective

57 lysis, glycoprotein IIb/IIIa inhibition, and low-molecular-weight heparin as adjuncts.

58 roach for the analysis of unfractionated and low molecular weight heparins, as well as porcine and hu

59 e of glycoprotein IIb/IIIa inhibitors and/or low-molecular-weight heparin before catheterization have

60 d Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Pla

61 h full versus prophylactic/intermediate-dose low-molecular-weight heparin bridging.

62 ial care was higher in patients who received low-molecular-weight heparin, but this was partly offset

63 in binding of various glycosaminoglycans and low molecular weight heparins by microscale thermophores

64 hrombotic agents (unfractionated heparin and low-molecular-weight heparin) can reduce the occurrence

65 edical-surgical critically ill patients, and low-molecular-weight heparin compared with bid unfractio

66 boembolic prophylaxis, cost-effectiveness of low-molecular-weight heparin compared with that of other

67 Preliminary studies suggest that low molecular weight heparins could have a role in the p

68 In contrast, two low molecular weight heparins currently considered as cl

69 Low-molecular weight heparins demonstrate at least equal

70 o major advances are IIb/IIIa inhibition and low-molecular-weight heparin, each of which significantl

71 sess whether antithrombotic prophylaxis with low-molecular-weight heparin effectively prevents recurr

72 pirin and heparin has been expanded with the low molecular weight heparin enoxaparin and the intraven

73 andards, and an in-depth NMR analysis of the low molecular weight heparin enoxaparin through systemat

74 se of the pentasaccharide, fondaparinux, and low molecular weight heparin enoxaparin.

75 HSQC spectra of GlcNS, fondaparinux, and the low-molecular weight heparin enoxaparin illustrate the p

76 Both heparin and the low-molecular weight heparin enoxaparin significantly in

77 lso detected heparin-based drugs such as the low-molecular-weight heparin enoxaparin (Lovenox) and th

78 pancreatic trypsin inhibitor is enhanced by low molecular weight heparin (enoxaparin).

79 In patients with acute coronary syndrome, low-molecular-weight heparin (enoxaparin) both improves

80 In the ESSENCE trial, subcutaneous low-molecular-weight heparin (enoxaparin) reduced the 30

81 This was reproducible with low-molecular-weight heparin (enoxaparin; K(i) = 70 +/-

82 r in combination with standard heparin and a low-molecular-weight heparin, enoxaparin, to suppress th

83 We compared a low-molecular-weight heparin, enoxaparin, with unfractio

84 ts did not differ from that with warfarin or low-molecular-weight heparin (factor Xa vs warfarin IRR

85 tPA was constructed by conjugating tPA with low-molecular weight heparin followed by complexation wi

86 r than conventional anticoagulation therapy (low-molecular-weight heparin followed by vitamin K antag

87 on whether they are antithrombin dependent (low-molecular-weight heparin, fondaparinux) or antithrom

88 eatments included substitution of heparin or low-molecular weight heparin for warfarin (n = 13 [72%])

89 ost patients received a prophylactic dose of low-molecular-weight heparin for a week and aspirin inde

90 oral anticoagulant compared with warfarin or low-molecular-weight heparin for all indications.

91 tal venous thromboembolism to receive either low-molecular-weight heparin for at least 5 days followe

92 ith heparin and then with either warfarin or low-molecular-weight heparin for at least three to six m

93 s of our trials showed that prophylaxis with low-molecular-weight heparin for the 8 days after knee a

94 s noninferior to perioperative bridging with low-molecular-weight heparin for the prevention of arter

95 lation would be noninferior to bridging with low-molecular-weight heparin for the prevention of perio

96 dditional clinical trials of edoxaban versus low-molecular-weight heparin for the treatment of venous

97 thromboembolism, and they are comparable to low-molecular-weight heparin for thromboprophylaxis afte

98 The optimal dosing strategy of low-molecular-weight heparins for the treatment of anten

99 fter discharge for 77 (1.5%) patients, and a low-molecular-weight-heparin for 60 (1.2%) patients.

100 ned to receive either a prophylactic dose of low-molecular-weight heparin (for the 8 days after arthr

101 studied the effects of UF-heparin and three low-molecular-weight heparin fractions (medium-molecular

102 a and to the characterization of heparin and low molecular weight heparin from different sources.

103 shown for chondroitin sulfate proteoglycans, low molecular weight heparins, full length heparins, and

104 for benefit with specific treatments such as low-molecular-weight heparins, glycoprotein IIb/IIIa inh

105 about the three classes of antithrombotics--low-molecular-weight heparins, GP IIb/IIIa inhibitors, a

106 Over the past few years, low molecular weight heparin has been well established a

107 Low-molecular-weight heparin has a more predictable anti

108 Low molecular weight heparins have the potential of bein

109 ant hirudin (parenteral DTI) and enoxaparin (low molecular weight heparin) have been demonstrated to

110 omplications in her 2 pregnancies asks: Will low-molecular-weight heparin help prevent recurrent plac

111 meta-analyses indicate that prophylaxis with low molecular weight heparin, heparin, or fondaparinux s

112 Interventions involving adjusted doses of low molecular weight heparin in combination with aspirin

113 The efficacy and safety of low molecular weight heparin in the prophylaxis of DVT f

114 ptor for the clearance of unfractionated and low molecular weight heparins in the liver.

115 s consisted of venous compression stockings, low-molecular weight heparin in obese patients, and earl

116 trials have focused on VTE prophylaxis with low-molecular weight heparins in high-risk cancer outpat

117 ead comparison of rivaroxaban with long-term low-molecular-weight heparin in patients with cancer is

118 aparinux demonstrated efficacy compared with low-molecular-weight heparin in randomized clinical tria

119 ageable after administration of prophylactic low-molecular-weight heparin in the combination group.

120 the role of antithrombotic prophylaxis with low-molecular-weight heparin in the prevention of recurr

121 Low-molecular-weight heparin (in comparison to unfractio

122 ate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein

123 For initial treatment, use of low-molecular-weight heparin increased from 77% to 84%,

124 Either (unfractionated) heparin or low molecular weight heparin is an acceptable treatment

125 Low-dose unfractionated heparin or low molecular weight heparin is preferred.

126 Low molecular weight heparin is the preferred initial th

127 Prophylactic use of warfarin or low-molecular weight heparin is not recommended, althoug

128 Low-molecular weight heparin is the preferred drug-based

129 nd placebo-controlled trial on the effect of low-molecular-weight heparin is lacking.

130 One study suggested that low-molecular-weight heparin is more efficacious than un

131 Although monotherapy with low-molecular-weight heparin is recommended in these pat

132 Low-molecular-weight heparin is recommended over warfari

133 Low-molecular-weight heparin is the standard treatment f

134 processes similar to ones used in preparing low-molecular-weight heparins is reported.

135 l calf compression devices and perioperative low molecular weight heparin, is approximately 2%.

136 Enoxaparin, a low-molecular weight heparin, is effective in prevention

137 ithrombotic treatment (low-dose aspirin plus low-molecular weight heparin [LDA+LMWH]) for obstetric a

138 red its antiallergic activity with that of a low molecular weight heparin (LMW-heparin, fragmin).

139 Low molecular weight heparin (LMWH) and direct thrombin

140 We have used low molecular weight heparin (LMWH) as a model for highl

141 experiment evaluated enterally administered low molecular weight heparin (LMWH) combined with sodium

142 The use of low molecular weight heparin (LMWH) during PCI has been

143 ncer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were el

144 The potential of low molecular weight heparin (LMWH) in anti-angiogenic t

145 to enhance the inhibitory effects of heparin/low molecular weight heparin (LMWH) in breast cancer cel

146 Low molecular weight heparin (LMWH) is being tested as a

147 We hypothesized that low molecular weight heparin (LMWH) is superior to unfra

148 Evidence has suggested that low molecular weight heparin (LMWH) might improve surviv

149 When AT was administered in combination with low molecular weight heparin (LMWH) or if LMWH was admin

150 r V Leiden are often treated with drugs like low molecular weight heparin (LMWH) to prevent placental

151 Low molecular weight heparin (LMWH), derived from hepari

152 anticoagulant functions of both heparin and low molecular weight heparin (LMWH), with reduced antige

153 ctivity, heparin affinity, and inhibition by low molecular weight heparin (LMWH).

154 Clinically used low molecular weight heparins (LMWH) are anticoagulants

155 asone should receive prophylaxis with either low-molecular weight heparin (LMWH) or low-dose aspirin.

156 asone should receive prophylaxis with either low-molecular weight heparin (LMWH) or low-dose aspirin.

157 PL) vesicles demonstrated that inhibition by low-molecular weight heparin (LMWH) was independent of f

158 He is treated with therapeutic doses of low-molecular weight heparin (LMWH), with brief interrup

159 Low-molecular weight heparins (LMWH) prepared by partial

160 mg/kg PO TID), OHEP only (30 mg/kg PO TID), low-molecular-weight heparin (LMWH) (enoxaparin 5 mg/kg

161 Low-molecular-weight heparin (LMWH) along with with vita

162 red with systemic anticoagulation by APC and low-molecular-weight heparin (LMWH) at doses that inhibi

163 We have shown previously that the GAG low-molecular-weight heparin (LMWH) binds to Abeta40 fib

164 studies have consistently demonstrated that low-molecular-weight heparin (LMWH) compounds are effect

165 tegies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding

166 evidence to support the substitution of the low-molecular-weight heparin (LMWH) enoxaparin for unfra

167 ada, since 2006, involved replacing UFH with low-molecular-weight heparin (LMWH) for prophylactic and

168 tients given unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) for prophylaxis or t

169 g events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomize

170 boprophylaxis with low-dose aspirin (ASA) or low-molecular-weight heparin (LMWH) in patients with new

171 Low-molecular-weight heparin (LMWH) is modestly superior

172 ve studies suggest that: long-term full-dose low-molecular-weight heparin (LMWH) is more effective th

173 A daily injection of low-molecular-weight heparin (LMWH) is often prescribed

174 Long-term low-molecular-weight heparin (LMWH) is the current stand

175 cular weight dependent, we hypothesized that low-molecular-weight heparin (LMWH) may have greater pot

176 Low-molecular-weight heparin (LMWH) offers pharmacologic

177 give us new information about the effects of low-molecular-weight heparin (LMWH) on pregnancy complic

178 Use of in-hospital thromboprophylaxis with low-molecular-weight heparin (LMWH) or low dose unfracti

179 etween perioperative thromboprophylaxis with low-molecular-weight heparin (LMWH) or unfractionated he

180 pid syndrome (APS) treated with prophylactic low-molecular-weight heparin (LMWH) plus low-dose aspiri

181 odology for the quantitation of a commercial low-molecular-weight heparin (LMWH) preparation (Fragmin

182 s further demonstrated for the analysis of a low-molecular-weight heparin (LMWH) preparation from por

183 partum period is not above a threshold where low-molecular-weight heparin (LMWH) prophylaxis is clear

184 K antagonist (VKA) throughout pregnancy; 2) low-molecular-weight heparin (LMWH) throughout pregnancy

185 andomized controlled trials (RCTs) comparing low-molecular-weight heparin (LMWH) vs no LMWH for the p

186 is of randomized controlled trials comparing low-molecular-weight heparin (LMWH) vs no LMWH in women

187 (UFH), its 16-, 8-, and 6-mer subfractions, low-molecular-weight heparin (LMWH), and the pentasaccha

188 nflammatory effects of aspirin, clopidogrel, low-molecular-weight heparin (LMWH), platelet glycoprote

189 e determined and compared with inhibition by low-molecular-weight heparin (LMWH).

190 rnatives to vitamin K antagonists (VKAs) and low-molecular-weight heparin (LMWH).

191 d a linear detection of both UFH (15kDa) and low-molecular-weight heparin (LMWH; 6kDa) added to human

192 Although heparin and low-molecular-weight heparins (LMWH) have been widely us

193 s6025 or F2 rs1799963 polymorphism (n = 279; low-molecular-weight heparin [LMWH] treatment during pre

194 ons (medium-molecular-weight heparin [MMWH]; low-molecular-weight heparin [LMWH]; and ultralow-molecu

195 The interaction of low-molecular-weight heparin (LMWHep) with the PrP N- or

196 results of recent clinical trials evaluating low molecular weight heparins (LMWHs) in the management

197 dings that anticoagulants, in particular the low molecular weight heparins (LMWHs), exert an antineop

198 Heparin and low-molecular weight heparins (LMWHs), complex, sulfated

199 To assess the safety and efficacy of low-molecular-weight heparins (LMWHs) for thromboprophyl

200 However, low-molecular-weight heparins (LMWHs) have practical and

201 Low-molecular-weight heparins (LMWHs) possess several po

202 oral vitamin K antagonists and subcutaneous low-molecular-weight heparins (LMWHs).

203 ly apart from unfractionated heparin include low-molecular-weight heparins (LMWHs); a pentasaccharide

204 ctin function, and the current switchover to low-molecular weight heparins may come at some loss of t

205 Low-molecular-weight heparins may simplify the managemen

206 Although low-molecular-weight heparin monotherapy has been identi

207 in the presence of either unfractionated or low-molecular-weight heparins more potently than factor

208 treated by anticoagulation with subcutaneous low-molecular-weight heparin (n = 15) or intravenous hep

209 VTE treatment consisted of subcutaneous low-molecular-weight heparin (n = 5) or intravenous hepa

210 (n=21 162), subcutaneous unfractio--nated or low-molecular-weight heparin (n=10 718), subcutaneous fo

211 This impurity has also contaminated low-molecular-weight heparins obtained by chemical and e

212 Low-molecular-weight heparins offer practical and potent

213 Venous thromboembolism prophylaxis with low molecular weight heparin or unfractionated heparin i

214 Fixed-dose low-molecular-weight heparin or adjusted-dose unfraction

215 ndromes, especially regarding treatment with low-molecular-weight heparin or IIB/IIIA inhibitors.

216 ceived anticoagulant thromboprophylaxis with low-molecular-weight heparin or unfractionated heparin a

217 Failure of standard thromboprophylaxis using low-molecular-weight heparin or unfractionated heparin i

218 s achieved by subcutaneous administration of low-molecular-weight heparin or with an orally active an

219 aneous injection of dalteparin (5,000 IU), a low molecular weight heparin, or placebo for 1 year.

220 itial treatment with unfractionated heparin, low-molecular-weight heparin, or fondaparinux, usually o

221 macologic thromboprophylaxis (e.g., aspirin, low-molecular-weight heparin, or unfractionated heparin)

222 Prophylaxis with aspirin, low-molecular-weight heparin, or warfarin has been shown

223 c compression boots, unfractionated heparin, low-molecular-weight heparin, or warfarin.

224 rction to receive either 1 mg of enoxaparin (low-molecular-weight heparin) per kilogram of body weigh

225 bivalirudin monotherapy vs unfractionated or low-molecular-weight heparin plus optional GPIs (control

226 monotherapy compared with unfractionated or low-molecular-weight heparin plus optional GPIs on 1-yea

227 tributes of unfractionated heparin (UFH) and low-molecular-weight heparin: Potent activity against fa

228 eflecting the composition of intact GAGs and low molecular weight heparin preparations.

229 use only the combination of anti-DC-SIGN and low-molecular-weight heparin prevented binding.

230 of reperfusion, anticoagulation therapy with low molecular weight heparin provides a clear additional

231 Compared with unfractionated heparin, low-molecular-weight heparin reduced rates of pulmonary

232 Compared with unfractionated heparin, low-molecular-weight heparins reduced mortality rates ov

233 Although low molecular weight heparin remains the first line in v

234 uation of anticoagulants, dose reduction, or low-molecular-weight heparin replacement.

235 ed for pharmacologic thromboprophylaxis; (4) low molecular weight heparin represents the preferred ag

236 nfractionated heparin (group A), twice daily low-molecular-weight heparin (reviparin) for 1 week (gro

237 the risk was not different between NOACs and low-molecular-weight heparin (RR, 2.13; 95% CI, 0.22-20.

238 For preventing thromboembolic recurrences, low-molecular-weight heparins seemed as effective as unf

239 aluated the efficacy and safety of the ultra-low-molecular-weight heparin semuloparin for prevention

240 idge" with an alternative agent, typically a low-molecular-weight heparin, should be used.

241 M118 is a novel low-molecular-weight heparin that has been rationally de

242 Furthermore, it has been suggested that low molecular weight heparin therapy may prolong surviva

243 Current guidelines recommend low-molecular-weight heparin therapy for prevention of P

244 25% less frequently in patients who received low-molecular-weight heparin, this treatment resulted in

245 Blocking endothelial cell activation by the low-molecular-weight heparin tinzaparin was accompanied

246 om 2 randomized, controlled trials comparing low-molecular-weight heparin to coumarin treatment in ca

247 Inpatient low-molecular-weight heparin treatment became cost savin

248 Low-molecular-weight heparin treatment increased quality

249 Low-molecular-weight heparin treatment reduces mortality

250 incremental cost-effectiveness of inpatient low-molecular-weight heparin treatment was $7820 per QAL

251 sion; or (4) received therapeutic dosages of low-molecular weight heparin, unfractionated heparin, or

252 Thromboprophylaxis and treatment of VTE with low-molecular-weight heparin, unfractionated heparin, or

253 lecular-weight heparin 1.02 [0.42-2.70]; and low-molecular-weight heparin vs dabigatran 0.67 [0.20-1.

254 Treatment with low-molecular-weight heparin was cost saving when as few

255 After the prophylactic low-molecular-weight heparin was instituted to prevent v

256 Low-molecular-weight heparin was the most commonly presc

257 Low-molecular-weight heparin was used in 88% of the preg

258 h the administration of therapeutic doses of low-molecular-weight heparin, we performed a matched, re

259 f seven porcine intestinal heparins and five low-molecular-weight heparins were analyzed by this meth

260 Finally, we demonstrated that low molecular weight heparin (which binds to thrombin ex

261 egnancy alter the pharmacokinetic profile of low-molecular-weight heparins, which has led to controve

262 Semuloparin is a novel ultra-low-molecular-weight heparin with high antifactor Xa and

263 eive either bivalirudin or unfractionated or low-molecular-weight heparin with optional glycoprotein

264 ins (unfractionated heparin, heparinoids, or low-molecular-weight heparin) with aspirin or placebo.

265 ibitors, chronic kidney disease, anemia, and low-molecular-weight heparin within 48-hour pre-PCI.

266 Drug Administration (FDA) approved a generic low-molecular-weight heparin without clinical safety or